None listed
Conditions
Interventions
Drug : Patients will be randomized in a 1:1 ratio of standard-dose CNI/MPA (standard group) to reduced CNI/mTOR inhibitor (rapamune group) within 24 hours before transplantation. The target trough lev
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Recipients who underwent ABOi KT meeting all of the following criteria will be enrolled in the study 1) aged over than 18 years and less than 60 years 2) patients willing and able to give informed consent
Exclusion criteria
Exclusion criteria: • Patients who have not received other organ transplantation • Patients with PRA (panel reactive antibody) test value > 50% • Patients with DSA(Donor specific antibody) MFI test value >3000 • Patients with positive Lymphocyte cross-match • History of malignancy of any organ system within 5years • Patients with active infection • Patients who received medication related with other clinical trials • Patients who had follwing conditions 1) Severe uncontrolled hypercholesterolemia or hypertriglyceridemia 2) Abnormal liver function (AST, ALT, ALKP, total bilirubin) : more than three times higher than the standard value 3) White blood cell count =3,000 /mm3 (or absulute neutrophile count <1,000 mm3) or platelet count =75,000 /mm3
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| binary composite of biopsy-proven acute rejection or eGFR,50 ml/min per 1.73 m2 | — |
Secondary
| Measure | Time frame |
|---|---|
| graft loss, infectious complications, and the frequency of B, T cell, regulatory T cell, and associated cytokines (IL-2, IL-4, IL-10, IL-17A, TNF- ß, and IFN-?). | — |
Countries
Korea, Republic of
Contacts
Public ContactHyunwook Kwon
Asan Medical Center
Outcome results
None listed